13F Holdings
中文EN

HALO HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%

Margins

Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%

Returns

ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x

Leverage & solvency

Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.40B$1.02B$829.25M$660.12M$443.31M
Cost of revenue$228.77M$159.42M$192.36M$139.30M$81.41M
Gross profit$1.17B$855.91M$636.89M$520.81M$361.90M
R&D expense$81.49M$79.05M$76.36M$66.61M$35.67M
SG&A expense$207.09M$154.34M$149.18M$143.53M$50.32M
Operating income$469.01M$551.48M$337.57M$267.53M$275.90M
Interest expense$18.13M$18.09M$18.76M$16.95M$7.53M
Pretax income$466.88M$557.13M$348.33M$248.92M$248.52M
Income tax$149.99M$113.04M$66.73M$46.79M-$154.19M
Net income$316.89M$444.09M$281.59M$202.13M$402.71M
EBITDA$480.39M$561.74M$348.66M$274.02M$278.90M
EPS (basic)2.643.502.131.482.86
EPS (diluted)2.563.432.101.442.74
Weighted avg. shares (diluted)123.90M129.42M134.20M140.61M146.80M
Balance sheet
Cash & equivalents$133.82M$115.85M$118.37M$234.69M$119.22M
Short-term investments———$128.60M$622.20M
Receivables$426.27M$288.20M$233.25M$186.97M$90.97M
Inventory$176.47M$141.86M$127.60M$100.12M$53.91M
Current assets$825.21M$1.09B$746.42M$739.01M$926.29M
PP&E, net$44.44M$40.86M$38.11M$35.10M$6.79M
Goodwill$580.36M$416.82M$416.82M$409.05M$0
Intangibles$981.47M$401.83M$472.88M$546.65M$0
Total assets$2.53B$2.06B$1.73B$1.84B$1.10B
Current liabilities$177.09M$139.10M$112.49M$130.79M$117.15M
Short-term debt$0$0$0$13.33M$89.42M
Long-term debt$2.14B$1.51B$1.50B$1.49B$787.25M
Total debt$2.14B$1.51B$1.50B$1.51B$876.67M
Total liabilities$2.48B$1.70B$1.65B$1.67B$907.48M
Shareholders' equity$48.81M$363.82M$83.81M$169.80M$196.95M
Net debt$2.01B$1.39B$1.38B$1.27B$757.46M
Shares outstanding117.78M123.14M126.77M135.15M137.50M
Cash flow statement
Operating cash flow$651.56M$479.06M$388.57M$240.11M$299.44M
Capital expenditure$6.97M$10.70M$15.29M$4.81M$1.46M
Free cash flow$644.59M$468.37M$373.28M$235.30M$297.98M
Investing cash flow-$545.81M-$262.72M-$96.91M-$487.00M-$406.29M
Financing cash flow-$85.17M-$218.86M-$407.99M$362.37M$77.86M
Depreciation & amortization$11.39M$10.26M$11.08M$6.49M$3.00M
Stock-based compensation$51.56M$43.38M$36.62M$24.40M$20.82M
Share buybacks$342.37M$250.00M$402.38M$200.00M$350.06M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.